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recommendations on CAM from friends and family members were tend not to
disclose their CAM use (r -0.17, p0.02). However those received recommenda-
tions from their health care providers were more likely to disclose CAM use (r0.3,
p0.001). Previous experiences of side effects due to CAM therapies was positively
correlated (r0.14, p0.04) with CAM disclosure behavior. CONCLUSIONS: Under-
standing the underlying beliefs of patients’ reluctance to disclose CAM usage to
health care providers is important especially when they are on active cancer treat-
ment. A friendly non-judgmental discussion about CAMuse by the physiciansmay
improve patients’ CAM behavior towards CAM disclosure.
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OBJECTIVES: Since the launch of imatinib in Taiwan, survival of chronic myeloid
leukemia (CML) has significantly improved with the cost of numerously increasing
drug expenditure. Neither health-related quality-of-life (QoL) of CML patients nor
long-term cost-effectiveness of imatinib, however, has been investigated in Tai-
wan. This study aimed to explore the feasibility of preference-based utility mea-
sures on CML patients with imatinib treatment. METHODS: This cross-sectional
survey was conducted at a medical center in southern Taiwan from June 2011 to
January 2012 after approved by the Institutional Review Board. CML outpatients
receiving imatinib were invited to participate the interviews; their QoL were mea-
sured by EuroQol group 5-dimension (EQ-5D) questionnaire, 100-mm visual ana-
logue scale (EQ-5D VAS) and time-trade-off (TTO) method, and then transformed
into utility value. Japanese preference weight was used to transform EQ-5D index
into utility. Patients’ demography, socioeconomic characteristics and progression
history were collected to adjust utility values by multiple regression. RESULTS: Of
the 42 (mean age: 50.016.0 years, male: 54.8%) participants, 36 (85.7%) have been
regularly followed up over 1.5 years, and 13 (31.0%) had history of progressing to
accelerated or blast phase. In EQ-5D survey,most participants choose “no problem”
in the domains of mobility, self-care, and usual activities, and 10 (23.8%) and 7
(16.7%) participants choose “some problem” in pain/discomfort and anxiety/de-
pression, respectively. Mean utility values and response rates for EQ-5D, EQ-5D
VAS, and TTO were 0.800.09 (100%), 0.780.13 (97.6%), and 0.800.18 (92.9%) and
there was no significant difference in utility between three measures. No associa-
tion between participant’ characteristics and utility was found, except for utility
derived from EQ-5D VAS was significantly associated with education level.
CONCLUSIONS: Preference-based utility measured are applicable to CML patients
receiving routine treatments. Since no Taiwanese preference weight for transfer-
ring EQ-5D assessment, further large-scale studies are needed, however, to vali-
date and cross-validate the measurements.
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OBJECTIVES: The JFMC37-0801 trial is a phase III trial designed to validate superi-
ority of 1-year treatment with capecitabine to 6 months treatment as adjuvant
chemotherapy for stage III colon cancer. Health related quality of life (HRQOL) and
cost-effectiveness have been evaluated as an additional study. We analyzed im-
pact of prolonged treatment with capecitabine on patients’ HRQOL. METHODS:
Capecitabine (2500mg/m2/day) was orally given on days 1-14, followed by a 7-day
rest. Enrolled patients were randomly assigned to group A (received 8 courses of
capecitabine) or group B (16 courses). In patients agreed to participate to the addi-
tional study, HRQOL was evaluated by self-administered questionnaire at the start
of the protocol treatment, 3, 6, 9, 12, 15 and 18months. The questionnaire includes
Functional Assessment of Cancer therapy-C (FACT-C) and EuroQol 5 Dimension
(EQ-5D). RESULTS: In 1306 patients enrolled to the JFMC37-0801 trial, HRQOL of 171
participants (81 in group A, 90 in group B) were evaluated. Mean age of the patients
in group A and B was 63.3 and 64.5 years-old, respectively. Among a total of 1197
points of survey, 959 questionnaires (80.1%) were retrieved. Recovery rates of ques-
tionnaires tended to decrease with time after finishing treatment. Through the
entire survey period, mean score of FACT-C (96.9-103) and EQ-5D (0.85-0.93) were
satisfactory. In longitudinal analysis of the change from baseline score, the scores
tended to increase after finishing the treatment period in both group A and group
B. Significant difference between the score of groupAand groupBwasnot observed
in each survey point. No difference by age and tumor stage was also observed.
CONCLUSIONS: HRQOL of the patients received postoperative adjuvant chemo-
therapy with capecitabine was satisfactory through the survey period. There was
no significant difference of HRQOL between 8 and 16 courses of capecitabine treat-
ment.
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OBJECTIVES: Prayers, spiritual healing, yoga, meditation, tai Chi, Qi gong, support
groups are classified as Mind Body Complementary Therapies (MBCTs). While the
benefits of MBCTs in cancer care is continued to be investigated, the prevalence of
such practices is notwell known amongMalaysian cancer patients. The study aims
to examine the prevalence of MBCTs use and its potential effects on Health related
quality of life (HRQoL) in a group of cancer patients. METHODS: This cross-sec-
tional study was undertaken with 393 cancer patients at the oncology wards of
Penang General Hospital, Malaysia. RESULTS: Out of 393 participants, 184 (46.1%)
were reported to use some type of Complementary and Alternative Medicines
(CAM). Among the CAM users, 75(40.7%) patients self reported using MBCTs for
their cancers. The majority of the MBCTs users were female (60/75, p0.01), aged
between 38 and 57 (44/75), and were from Malay ethnicity (46/75). Socio-demo-
graphic factors including age (r0.15, p0.03) and monthly house hold income (r
-0.25, p0.001)were strongly correlatedwithMBCTs use. Prayers for health reasons
was the highest 51 (27.7%), followed by spiritual practices 20(10.8%), meditation
7(5.9%), tai chi 7(3.8%), music therapy 4(2.1%), Qigong 1(0.5%), hypnotherapy
1(0.5%), and reiki 1(0.5%). Recommendations from friends and family members
53(70%) were the most common reasons of MBCTs use followed by patient’s own
will 22(29.3%). Health related Quality of Life (HRQoL) scores shows significant dif-
ference in functional and symptoms scores among MBCTs users and non-users.
CONCLUSIONS:Nearly half of the CAMusers utilized some types ofMBCTs. Prayers
specifically for health reasons and spiritual practices are somewhat common
among cancer patients. Viewing MBCTs not as alternative but to complement can-
cer therapies to address emotional and psychological needsmay help in improving
health related quality of life (HRQoL) of cancer patients.
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OBJECTIVES: To examine the prevalence of CAM use among Malaysian cancer
patients and compare the differences in health-related quality of life (HRQoL) be-
tween CAM users and non-users. METHODS: This cross-sectional study was un-
dertaken with 393 patients at the oncology wards of Penang General Hospital,
Malaysia. The HRQoL between CAM users and non-users was assessed by using
European Organization for Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLQ-C30). RESULTS: The majority (46.1%) of the participants
were frequent CAM users. The most common CAM therapies were dietary and
nutritional supplements (41.3%), herbal products (30.4%), prayers for health rea-
sons including spirituality (22.8%), traditional Malay therapies (20.11%) and Tradi-
tional Chinese Medicines (14.1%). No significant difference was found between
functional and symptoms scores among CAM users and non-users. However;
global health scores/quality of life was significantly different (P0.002) between
CAM users and non-users. CONCLUSIONS: Patients’ interest in the use of CAM
highlights the need of greater health care education in this field. This study pro-
vides evidence of CAM use and its overall effects on quality of life scores in a
sample of patients with cancer. Patients should be aware of the potential benefits
of CAM therapies for cancer. Health care professionals can play their role effec-
tively to encourage patients towards rational use of CAM therapies.
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OBJECTIVES: To assess quality of Life (QoL) among cancer patients receiving cape-
citabine at Nakhon Pathom Hospital in Thailand. METHODS: Cancer patients re-
ceiving capecitabine, either as monotherapy or in combination with other anti-
cancer drugs, at Nakhon PathomHospital, were recruited during July to September
2011. The Thai version of the Functional Assessment of Cancer Therapy-General
(FACT-G) comprising four subscales, physical well-being (PWB), social/family well-
being (SWB), emotional well-being (EWB) and functional well-being (FWB), was
utilized to assess QoL of these patients. Demographic data (age, gender,status,
educational level, occupation, and monthly income) as well as medical history
(type, stage and duration of cancer) of the patients were also collected. RESULTS:
Altogether 13 patients receiving capecitabinemonotherapy and 24 patients receiv-
ing capecitabine combination therapywere recruited in this study. Theirmean (SD)
overall QoL score was 51.66 (9.33) from 108 . While the mean (SD) scores for PWB,
SWB, EWB and FWB subscales were 8.60 (5.86), 19.91 (5.75) from 28, 7.38 (4.96) from
24 and 15.77 (7.88) from 28, respectively. The mean QoL in this group of patients
were lower than normaltive data. Only subscal SBW that higher than normative
data. The score of BEWPWBFWBSWB. No significant relationship was re-
vealed between demographic data and any subscales of the FACT-G in patients
receiving capecitabine monotherapy, CONCLUSIONS: The QoL in patients who
receive capecitabinemonotherapy are lower thannormative data. Even though , no
relationships are found between demographic data and any subscales. The activ-
ities to improve patients’ emotion should be establish to improve quality of life of
the patients.
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